Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Utah: - American Fork Hospital / Huntsman Intermountain Cancer Center — American Fork, Utah
- Sandra L Maxwell Cancer Center — Cedar City, Utah
- Farmington Health Center — Farmington, Utah
- Logan Regional Hospital — Logan, Utah
- Intermountain Medical Center — Murray, Utah
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Utah: - Intermountain Medical Center — Murray, Utah
- LDS Hospital — Salt Lake City, Utah
- Saint George Regional Medical Center — St. George, Utah
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 2, Phase 3 Recruiting Industry
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in Utah: - Utah Intermountain Medical Center — Murray, Utah
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Sites in Utah: - Intermountain Health — Murray, Utah
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
Sponsor: AstraZeneca
NCT ID: NCT07611110
Sites in Utah: - Research Site — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of A…
Sponsor: AstraZeneca
NCT ID: NCT07336446
Sites in Utah: - Research Site — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
Sponsor: MBrace Therapeutics
NCT ID: NCT07145255
Sites in Utah: - START, Mountain Region — West Valley City, Utah
Phase 1, Phase 2 Recruiting Industry
This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.
Sponsor: GlaxoSmithKline
NCT ID: NCT07332455
Sites in Utah: - GSK Investigational Site — West Valley City, Utah
Phase 2 Recruiting Academic/Other
This trial will evaluate whether the immune-sensitizing effects of immunotherapy (Pembrolizumab) and radiation with or without a PARP-inhibitor (Olaparib) will increase the effects of immunotherapy in men with high-risk localized prostate …
Sponsor: Zin W Myint
NCT ID: NCT05568550
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
The purpose of this study is to determine how well the study drug XL092 is helping to treat a participant's cancer after 16 weeks of treatment. Researchers will also look at how safe the XL092 is and how well the XL092 is working. XL092 is…
Sponsor: University of Utah
NCT ID: NCT06568562
Sites in Utah: - Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.
Sponsor: University of Utah
NCT ID: NCT07216248
Sites in Utah: - Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
Phase 1 Recruiting Industry
The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amen…
Sponsor: Amgen
NCT ID: NCT04221542
Sites in Utah: - Intermountain Medical Center — Murray, Utah
Phase 1 Recruiting Industry
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharm…
Sponsor: IDEAYA Biosciences
NCT ID: NCT07540572
Sites in Utah: - START Mountain Region, LLC — West Valley City, Utah
Phase 1 Recruiting Industry
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tu…
Sponsor: MacroGenics
NCT ID: NCT06242470
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 1 Recruiting Industry
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
NCT ID: NCT07517198
Sites in Utah: - START Mountain Region — West Valley City, Utah
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Utah: - Massive Bio SYNERGY-AI site — Salt Lake City, Utah
NA Recruiting Academic/Other
Prostate cancer has a significant impact on patient quality of life (QoL) directly, as well as through the management of localized disease (such as surgery and radiation-related incontinence, erectile dysfunction, and bowel dysfunction), a…
Sponsor: University of Utah
NCT ID: NCT07093177
Sites in Utah: - Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah